beta -Amyloid protein (A beta), a 39-42 residue peptide resulting from the
proteolytic processing of a membrane-bound beta -amyloid precursor protein
(APP), is one of the major components of the fibrillar deposits observed in
Alzheimer patients. A beta fibril formation is a complex process which inv
olves changes in A beta conformation and self-association to form cross-bet
a pleated sheets, protofibrils, and fibrils. Since the aggregation of solub
le A beta peptide into fibrils is viewed as a critical event in the physiop
athology of Alzheimer's disease (AD), preventing, altering, or reversing fi
bril formation may thus be of therapeutic value. This review will focus on
the current state of knowledge of A beta fibril formation, with special emp
hasis on physiological and exogenous inhibitors which may have a therapeuti
c potential. (C) 2001 Editions scientifiques et medicales Elsevier SAS.